Compugen (NASDAQ:CGEN) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Compugen (NASDAQ:CGEN) announced its earnings results on Monday. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.04, Morningstar.com reports.

Shares of CGEN stock traded up $0.32 on Tuesday, hitting $3.33. The company had a trading volume of 11,259 shares, compared to its average volume of 336,832. The stock has a market capitalization of $163.11 million, a price-to-earnings ratio of -8.12 and a beta of 2.65. The company’s 50-day simple moving average is $3.54. The company has a current ratio of 5.11, a quick ratio of 5.11 and a debt-to-equity ratio of 0.11. Compugen has a twelve month low of $2.00 and a twelve month high of $4.31.

Several hedge funds have recently modified their holdings of CGEN. ARK Investment Management LLC increased its stake in Compugen by 3.2% during the 2nd quarter. ARK Investment Management LLC now owns 8,496,641 shares of the biotechnology company’s stock worth $32,627,000 after buying an additional 267,086 shares in the last quarter. Nikko Asset Management Americas Inc. grew its position in shares of Compugen by 84.0% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,631,037 shares of the biotechnology company’s stock valued at $6,263,000 after purchasing an additional 744,447 shares in the last quarter. Taylor Frigon Capital Management LLC grew its position in shares of Compugen by 11.5% in the second quarter. Taylor Frigon Capital Management LLC now owns 760,424 shares of the biotechnology company’s stock valued at $2,920,000 after purchasing an additional 78,278 shares in the last quarter. Defender Capital LLC. grew its position in shares of Compugen by 7.2% in the first quarter. Defender Capital LLC. now owns 311,333 shares of the biotechnology company’s stock valued at $1,299,000 after purchasing an additional 20,800 shares in the last quarter. Finally, Stockman Wealth Management Inc. purchased a new stake in shares of Compugen in the first quarter valued at approximately $286,000. 29.43% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research downgraded Compugen from a “buy” rating to a “hold” rating in a research note on Monday, July 29th.

Compugen Company Profile

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Further Reading: Roth IRA

Earnings History for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.